Table 1

Antitumor activity of gefitinib and cetuximab, given alone or in combination against A431 tumors xenografted in nude mice

Study designTreatmentTumor-growth inhibition (% of control)*Tumor-free mice (no. of remissions/total)Body weight (mean g ± SEM)
CompoundDose
I0/1019.1 ± 1.7
gefitinib25 mg/kg200/1020.6 ± 0.2
gefitinib50 mg/kg610/1020.2 ± 0.4
cetuximab1 mg/mouse250/1021.1 ± 0.3
gefitinib + cetuximab25 mg/kg + 1 mg/mouse923/1020.6 ± 0.4
gefitinib + cetuximab50 mg/kg + 1 mg/mouse10010/1019.0 ± 0.3
II0/1223.2 ± 0.5
gefitinib50 mg/kg120/1220.7 ± 0.6
gefitinib100 mg/kg370/1220.4 ± 0.8
cetuximab1 mg/mouse310/1222.4 ± 0.5
cetuximab1.5 mg/mouse640/1222.3 ± 0.6
gefitinib + cetuximab50 mg/kg + 1.5 mg/mouse9911/1219.7 ± 0.5
gefitinib + cetuximab100 mg/kg + 1.5 mg/mouse10012/1219.0 ± 0.4
III0/1022.0 ± 0.8
gefitinib50 mg/kg770/1020.0 ± 0.6
gefitinib200 mg/kg10010/1018.0 ± 0.6
cetuximab1 mg/mouse312/1021.9 ± 0.5
cetuximab1.5 mg/mouse876/1021.2 ± 0.4
gefitinib + cetuximab50 mg/kg + 1 mg/mouse10010/1020.3 ± 0.3
  • Note. Study design I and III treatment was initiated when tumors were ∼200 mm3 in size; study design II treatment was initiated when tumors were ∼500 mm3 in size.

  • * Percentage of tumor growth inhibition relative to control, at the end of the treatment (study design I, day 31; study design II, day 36; study design III, day 34).

  • Tumor-free animals/total number of animals, at the end of the treatment.

  • Body weight at the end of the treatment.